Mutant IDH1 is an effective immunotherapeutic target for glioma

Cancer Discov. 2014 Sep;4(9):OF13. doi: 10.1158/2159-8290.CD-RW2014-145. Epub 2014 Jul 9.

Abstract

A neoantigen derived from mutant IDH1 can promote antitumor CD4(+) T-cell and antibody responses.

Publication types

  • Comment

MeSH terms

  • Animals
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use*
  • Female
  • Glioma / immunology*
  • Glioma / therapy*
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Isocitrate Dehydrogenase / immunology*
  • Male
  • Mutant Proteins / immunology*

Substances

  • Cancer Vaccines
  • Mutant Proteins
  • Isocitrate Dehydrogenase